Register Now: Hear from AliveCor's founder, Dr David, on his personal journey, the genesis of AliveCor, and his vision for the future of cardiology

AliveCor Logo

Our Products

KardiaMobile 6L
InstantQT
KardiaPro
Kardia ECG Devices

Our Solutions

AF Screening
Data Integration Solutions
Healthcare Providers
BioPharma

About

Leadership
Mission
Clinical Research
Newsroom
Shop all Products
Resource Hub
Contact Us
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • Mission
    • Leadership
    • Research
    • Careers
    • Newsroom
    • Resource Hub
    • FAQs
    • User Manuals
    • Shipping
    • Warranty
    • Resellers
    • Integration
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
    • Modern Slavery Statement
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Patient-Centric AF Screening

Early detection of arrhythmias is possible with Kardia screening program, a home-based screening program that is easy for at-risk members to follow, for short or long-term monitoring.

Contact Us

US AFIB Prevalence is significantly undetected

40%

of AF patients are asymptomatic

20%

of patients’ first clinical manifestation of AF is stroke²

$8.7k

AF can increase annual health care costs by $8700 per patient³

KardiaMobile®

Proven to detect undiagnosed AF & reduce total cost of care⁴

check-icon#1 patient-preferred personal ECG brand with high satisfaction
check-iconEasy to use for long-term monitoring with no uncomfortable patches or wires
check-iconCE-marked and FDA-cleared, instant heart rhythm determination gives patients peace of mind

KardiaMobile® detected more AF than routine care

REHEARSE-AF Study found a nearly 4x increase in AF detection in KardiaMobile group compared to routine care alone.⁴

  • RCT (n=1001) using KardiaMobile for AF screening
  • Patients aged ≥ 65 with CHADS-VASc score ≥ 2
  • ECGs captured 2x weekly over 12 months (or if symptomatic)

How It Works

masolutions.step1.title

Step 1

Patient receives KardiaMobile ECG device for real-time monitoring.

masolutions.step2.title

Step 2

If possible arrhythmia detected, patient discusses with healthcare professional to determine appropriate action cardiac tech reviews ECG within 24 hrs and sends to cardiologist for confirmation.

References
  1. Boriani, et al. "Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry." Am J Med vol. 128,5 (2015): 509-518.2.
  2. Tayal, A Het al. "Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke." Neurology vol. 71,21 (2008): 1696-701.
  3. Calkins, Het al. "HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation." Heart Rhythm vol. 14, 10 (2017): e275-444.
  4. Halcox, J P Jet al. "Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study." Circulation vol. 136,19 (2017): 1784-1794.